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Highlights 
 
• Method for estimating the fracture risk in osteoporotic patients based on Damage and Fracture 
Mechanics and DXA measurements. 
 
• The method evaluates the evolution over time of the mechanical strength of bone from BMD, for 
different treatments. 
 
• Evolutionary algorithm and a finite element model of the lumbar spine allow the prediction of fracture 
probability. 
 
• The incorporation of clinical measurements and simulation results will be useful for an individualized 
treatment in patients. 
 
• The model predicts the evolution of vertebral fracture probability and the expected evolution under 
different therapies. 
 
Abstract: Osteoporotic vertebral fractures represent major cause of disability, loss of quality of life and even mortality 
among the elderly population. Decisions on drug therapy are based on the assessment of risk factors for fracture, from bone 
mineral density (BMD) measurements.  
A previously developed model, based on the Damage and Fracture Mechanics, was applied for evaluating the mechanical 
magnitudes involved in the fracture process from clinical BMD measurements. BMD evolution in untreated patients and in 
patients with seven different treatments was analyzed from clinical studies, in order to compare the variation in the risk of 
fracture. The predictive model was applied in a finite element simulation of the whole lumbar spine, obtaining detailed maps 
of damage and fracture probability, identifying high-risk local zones at vertebral body.  
For every vertebra, strontium ranelate exhibits the highest decrease, whereas minimum decrease is achieved with oral 
ibandronate. All the treatments manifest similar trends for every vertebra. Conversely, for the natural BMD evolution, as 
bone stiffness decreases, the mechanical damage and fracture probability show a significant increase (as it occurs in the 
natural history of BMD). Vertebral walls and external areas of vertebral end plates are the zones at greatest risk, in 
coincidence with the typical locations of osteoporotic fractures, characterized by a vertebral crushing due to the collapse of 
vertebral walls 
This methodology could be applied for an individual patient, in order to obtain the trends corresponding to different 
treatments, identifying at-risk individuals in early stages of osteoporosis and might be helpful for treatment decisions.  
Keywords: Osteoporosis, osteoporotic vertebral fracture, predictive model, finite elements, fracture risk, fracture probability, 
osteoporosis treatments. 
1 Introduction 
Osteoporosis is a systemic skeletal disease characterized 
by low bone mass and deterioration of bone 
microstructure, leading to bone fragility and susceptibility 
to fracture [1]. Currently, osteoporotic fractures are 
considered as an important public health problem leading 
to morbidity and mortality, generating very important 
economic costs [2]. Osteoporosis represents a major cause 
of disability, loss of quality of life and even death among 
the elderly population [3-6]. 
Osteoporosis is caused by a skeletal involution linked to 
aging, which is more prevalent in women: the lifetime 
risk for a fragility fracture at the age of 50 lies within the 
range of 40% in women [7]. Osteoporosis has been called 
the silent epidemic because in most cases the first 
symptom is the appearance of a first fragility fracture, so 
it is essential to establish treatment to prevent fractures. 
The decision to treat is based on the analysis of risk 
factors for fracture.  
Vertebral fracture is the most common osteoporotic 
fracture, being more prevalent in women than in men [8, 
9], leading to back pain, kyphosis and severe functional 
and vital impact in 30-50% of patients [10, 11]. 
Underdiagnosis of osteoporotic vertebral fracture is 
common for lack of complementary tests in older women 
who visit the doctor complaining of back pain and 
sometimes because the symptomatology of the first 
fracture is not evident [12, 13].  
Different publications estimate that are diagnosed only 
40% of fractures [12, 14]; other assessments estimate that 
only 5-20% of these vertebral fractures are diagnosed in 
primary care [15]. The first vertebral fracture is a factor of 
high risk of new fractures, localized in another vertebra or 
other areas of skeleton [16-20], leading to so-called 
fracture cascade [21], when new fractures occur in the 
spine. Decisions on drug therapy in osteoporotic patients 
without previous fractures are mainly based on the 
analysis of risk factors which predispose to fracture. A 
risk assessment tool called FRAX® (Fracture Risk 
Assessment Tool) has been developed by the World 
Health Organization (WHO) for this purpose [7, 22-24]. 
The risk of major osteoporotic fractures (hip, vertebrae, 
humerus and wrist) over the next 10 years can be 
estimated with the FRAX® tool. The probability of 
fracture is calculated on the basis of age, body mass index 
and several dichotomized variables (previous fracture, 
smoking, rheumatoid arthritis, etc.). Other studies have 
questioned the effectiveness of FRAX® as a tool for 
predicting fracture risk [25-28]. 
Several previous surveys have assessed the risk of 
fracture using various methodologies, but mostly based on 
BMD measurements [29, 30] which is considered to be 
the most important indicator to diagnose osteoporosis and 
monitoring treatment [31]. BMD measurements have also 
been used for determining the mechanical strength [32] or 
to develop statistical models for predicting the risk of 
fracture [29, 30, 33-35].  
The treatment of osteoporosis includes general measures 
(breaking harmful habits, proper nutrition, physical 
exercise and prevention of falls, intake of Calcium and 
Vitamin D) and pharmacological treatment. The drugs 
used today are cost-effective [36]. Various medications 
are available for prevention and treatment of osteoporosis. 
Pharmacologic interventions preventing fractures in 
patients with osteoporosis aim at correcting the bone 
remodeling imbalance by either reducing bone resorption 
and bone turnover or stimulating bone formation and  
strontium ranelate both inhibits bone resorption and 
stimulates bone formation which gives a mixed effect [37, 
38]; this last drug is approved in Europe but not in USA. 
The fundamental aim of pharmacological treatment is to 
increase BMD, reducing resorption and bone turnover or 
stimulating bone formation, but not all drugs have the 
same effect and the increase percentages in BMD are 
different. 
In the field of Finite Element (FE) simulation, different 
models and methodologies were used for predicting bone 
strength or fracture risk at different ages and locations. 
So, Lee et al. (2004) [19] present a micromechanical 
model of bone behaviour, which is difficult to extrapolate 
to the scale required to get realistic predictions. Boccaccio 
et al. (2008) and Zhang et al. (2010) [39, 40] develop 
more advanced macro-mechanical models, analyzing a 
complete functional unit of the spine in terms of 
mechanical behaviour depending on bone density. 
MacNeil et al. (2012) [41] build a 2D model in the sagittal 
plane, using bone geometry and BMD measurements 
obtained from radiographs and Dual-energy X-ray 
Absorptiometry (DXA), calculating the stiffness in terms 
of patient's age. For proximal femoral fractures, Kaneko 
et al. (2011) [42] develop a model based on imaging 
techniques, establishing a statistical correlation between 
the prediction of bone strength and the risk of 
osteoporotic fracture. A different methodology is applied 
by Bryan et al. (2009) [43], who suggest a parametric 
model incorporating both the geometry and the properties 
of bone. A similar methodology is used by Bessho et al. 
(2009) [44], with a parametric analysis concerning load 
and support conditions. Some authors have begun to 
incorporate yield criteria for fracture risk prediction, as 
Derikx et al. (2011) [45] who apply the Drucker-Prager 
criterion on a model made from Quantitative Computed 
Tomography (QCT), with asymmetric yielding in tension 
and compression. In a similar way, Tellache et al. (2009) 
[46] apply an anisotropic yield criterion on a model 
constructed from Computed Tomography (CT) for 
predicting fracture risk. With a different approach, Amin, 
et al. (2011) [47] performed a comparative analysis of 
fracture risk predictions based on BMD measurements 
against those ones obtained from an FE model developed 
from QCT. Finally, on the matter of drug treatments, 
Keaveny et al. (2008) [48] analyze the influence on bone 
strength of Parathyroid Hormone (PTH) and alendronate, 
using a FE model developed from QCT scans of 
osteoporotic patients.  
Currently, the most popular clinical tool for fracture risk 
assessment is FRAX®, which doesn’t consider bone 
strength as a relevant magnitude. All the aforementioned 
computational methods use clinical or mechanical 
magnitudes related to bone fracture in an independent 
way, without consider their mutual influence as actually 
happens.  
The aim of this work is to apply a numerical model, 
previously developed [49], for predicting the risk of 
osteoporotic vertebral fractures based on the Damage 
Mechanics and Fracture Mechanics, both for the natural 
BMD evolution and seven different treatments in order to 
compare the variation in the risk of fracture. The proposed 
model allows establishing direct relationships between 
clinical and mechanical magnitudes, so evolution of 
BMD, bone strength, damage and fracture probability can 
be simultaneously evaluated at any age form the initial 
measurements of BMD. It is not intended to replace the 
models based solely on BMD, but to complement it 
including mechanical magnitudes involved in the 
fracturing process, providing more information on the 
mechanical state of the bone in every analyzed zone at 
each age.   
The novelty of this work compared to previous 
publications of the authors resides, firstly, in the extension 
to the whole of the lumbar spine, and on the other hand, in 
the application of the most common treatments in 
osteoporotic patients. 
 
2 Methods 
BMD is the current standard for diagnosis of osteoporosis. 
Over 120 worldwide published papers assessing lumbar 
spine BMD evolution, both in natural conditions and in 
patients under drug therapy, were selected for analysis. 
Regarding the natural history of BMD, the average curve 
published by Mazess and Barden (1999) [50] were chosen 
as a reference. For drug therapy, seven treatments were 
selected for the comparative study: oral ibandronate (100 
mg/month) [51], oral ibandronate (150 mg/month) [51], 
intravenous ibandronate (2 mg bimonthly) [52], 
intravenous ibandronate (3 mg quarterly) [52], strontium 
ranelate (2 g/day) [53], zoledronic acid (5 mg/year) [54] 
and Denosumab (60 mg every six months)[55]. These 
drugs have proven to be effective, and their BMD 
evolutionary curves show the required regularity during 
analyzed time period to be used in a numerical simulation.  
Bisphosphonates settle in the bone tissue and its effect 
persists during some time after its administration, and 
hence it is completely accepted in the clinical practice the 
use of intermittent or discontinuous treatments. For the 
ibandronate, several studies with different dosages [51, 
52] corroborate its effectiveness, decreasing the risk of 
vertebral fractures in women with osteoporosis, 
improving even in week dosage the results obtained with 
alendronate [56]. 
Strontium ranelate is an oral drug that enhances pre-
osteoblastic cell replication and osteoblastic 
differentiation and decreasing abilities of osteoblasts to 
induce osteoclastogenesis via the calcium sensing 
receptor and an increase in the OPG/RANKL ratio [57, 
58]. Moreover, it decreases bone resorption by inhibition 
of osteoclast resorbing activity and osteoclastic 
differentiation [59]. This dual mode of action leads to a 
rebalance in bone turnover and therefore in an 
improvement of bone strength [60]. In this case, BMD 
data are not comparable with others treatments because 
strontium has an atomic weight higher than calcium, 
distorting DXA measurements. A correction about 50% 
must be done in order to compare with other treatments 
[61]. 
Zoledronic acid, a third-generation aminobisphosphonate, 
slows down bone resorption, allowing the bone-forming 
cells time to rebuild normal bone architecture and 
allowing bone remodelling. Its final effect appears as a 
higher trabecular bone volume and number of trabeculae, 
lower trabecular separation and higher connectivity 
among trabeculae. It has shown marked efficacy reducing 
the risk of vertebral fractures in clinical trials, producing 
significant reductions in new fractures in postmenopausal 
women with osteoporosis [54]. 
Finally, with respect to the use of Denosumab, its action 
principle deals with the blocking of natural bone 
resorption. Its effectiveness reducing the fracture risk has 
been demonstrated in different studies a 5 and 8 years 
studies [62, 63], being recommendable its use in women 
with a high fracture risk. 
As the model evaluates the mechanical strength of bone 
from BMD, an analytical function expressing its evolution 
over time, obtained from numerical data contained in the 
different studies, is needed. Since the standard adjustment 
techniques (linear or quadratic regression curves) do not 
provide enough accuracy and reliability to be applied to 
the predictive model, more complex adjustments have 
been set out to obtain continuous curves of regression. 
The evolution trends of the different selected cases in the 
study can be extrapolated from those continuous curves, 
ensuring a consistent behaviour. The following 
adjustments were proposed for the apparent density ρ: 
- Polynomial: 
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where t is the age at which apparent density is calculated, 
n is the polynomial degree and k is an amplitude factor 
multiplying the normalized exponential function. 
These adjustments (Equations 1, 2 and 3) have been 
applied to the eight examined curves (natural evolution 
and the seven therapies). These equations apply to 
different treatments, as detailed in the Results section. 
Several requirements have been made during this 
adjustment: the lowest mean square error, the closest to 
unity correlation coefficient R2, and a 10-year 
standardized follow-up period. That extrapolation is 
intended to be consistent in mathematical terms, 
independently of the actual duration of the considered 
study. Standardization of BMD measurements included in 
each published paper was required in order to make 
comparisons among them [64], because the data were 
obtained from different densitometric equipment 
depending on the study (Hologic, Lunar and Norland). 
In order to assess the different treatments, the predictive 
model presented in [49] was applied to the different BMD 
evolutionary curves. As the predictive model takes into 
account the mechanical parameters involved in the 
fracture process, a correlation between these magnitudes 
and those ones measured in clinical terms is firstly 
required. To this effect, Carter and Hayes (1977) [65] 
established a direct relationship between Young's 
modulus, E, and bone apparent density, ρ, for low strain 
rates (0.01): 
 
32875E  (4) 
On the other hand, the relationship between the BMD 
value and the apparent density is adjusted, according to 
BMD clinical measurements and experimental results for 
apparent density [64], as:  
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being λ a numerical parameter that depends on the sample 
data. For the present study a value of 0.6 was assigned for 
λ in order to fit the actual data presented in [64]; max is 
the maximum value for apparent density, BMDmax is the 
maximum value for BMD and BMD is the actual value for  
BMD. 
The Karganovin´s Damage Mechanics model [66] was 
selected for the simulation of the degenerative process.  
A model of fracture probability based on the law of Paris 
[67], which explains the stable crack growth under 
monotonic loading, was developed [49]. According to 
such law, the rate of crack growth (differential 
relationship between number of stress cycles, N, and 
crack length, a)   is expressed as: 
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By integrating equation (6), the number of loading cycles, 
Ni-c, needed to increase mechanical damage from the Di 
value to the Dc value was expressed as follows: 
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where  and  are material parameters associated with the 
law of Paris [67],  is a parameter related to the stress 
intensity factor defined in Linear Elastic Fracture 
Mechanics, which depends on geometric aspects and 
stress distribution,   is the average variation of stress in 
each loading cycle and  is a parameter which relates the 
mechanical damage to the crack size a (a=D). 
By normalizing the probability of fracture, assigning 
value 1 to critical damage (D=Dcri) and value 0 to no 
damage (D=0), and assuming that the average variation of 
stress in each loading cycle remains constant, we finally 
obtain the probability of fracture as a function of the 
initial, Di, the current, Dc, and the critical, Dcrí, damages: 
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In the above expression, Di is the damage corresponding 
to the mechanical situation of the bone at the age of the 
patient and Dc is the estimated damage for the time at 
which fracture probability is evaluated. If no initial 
damage, Di, is detected, the probability is calculated as: 
 
 
1
2
)(






crí
c
c D
D
DP
 (9) 
 
Initial damage, Di, is obtained considering the mechanical 
properties corresponding to the actual age of the patient. 
In this way, only mechanical damage (D) and  
coefficient are needed in order to calculate the fracture 
probability. 
A value 5 has been given to the  coefficient for cortical 
bone, according to Taylor [68]  , and, in accordance with 
Kargarnovin et al. [66], a critical damage, Dcri, of 0.38 
and a critical strain, cri, of 0.0174 have been considered, 
with a variable strain threshold, 0, according to age 
(Figure 1) with a variation equivalent to the 
corresponding to BMD evolution (no damage is produced 
by strains below strain threshold). 
BMD evolutionary curves for a specific population are 
basic references and provide only general information. In 
order to apply the model to specific patients we must 
consider, in addition to the trend, the reference density 
value measured for the patient. In accordance with the law 
of interpolated natural evolution, the density matching 
with the age of the patient, )(tNp , is given by: 
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being N(t0) the average density measured in the patient 
and 0 the matching value from the reference progression 
curve, that is, the actual patient’s density that may be 
different to the average curve considered for the whole 
population. In fact, there is an offset that should be added 
to the reference evolutionary curve of density, providing a 
translation of the average curve, allowing an adaptation 
for each individual patient. 
 
Figure 1 – Evolutionary curves for strain threshold (natural evolution and the seven treatments): a) L1; b) L2; c) L3; d) L4 
When a drug therapy is applied to the same patient, a 
similar correction is required because a new offset 
appears. So, the progression curve for this patient under a 
treatment would be: 
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In Equations 10 and 11, the subscripts or superscripts N 
and T represent natural evolution or evolution with 
treatment, respectively. All these adjustments provide the 
estimated BMD value for a specific patient at any age and 
under any prescribed therapy. From this value, 
mechanical properties of bone can be calculated. It must 
be noticed that the considered curves represent the mean 
evolutionary curves for the population, and an individual 
patient could not follow the curve exactly but in an 
approximate way. 
Densitometric data of the healthy lumbar spine have been 
taken as the starting point for this study, based on 
previous published work [50]. As only information 
corresponding to 2D average values was available from 
BMD measurements for every vertebra and the vertebra 
includes five zones with different apparent density and 
bone properties as it is well known [69], an algorithm was 
implemented in order to assign the values corresponding 
to every zone. Firstly a mean value was defined for the 
apparent density by accounting the volume of every zone 
with its corresponding density (i.e., addition of the 
product of volume times density divided by the total 
volume). Then that mean value was obtained from 
equation (5) for every vertebra. Finally, performing the 
inverse process specific values of BMD apparent density 
and Young modulus were assigned to each of the five 
zones (Table 1). This procedure is repeated along the 
evolutionary process. 
From all the previous calculations, an evolutionary 
algorithm has been implemented (Figure 2), which has 
been used combined with a finite element model of the 
spine containing T12-S1 segments (Figure 3), obtained 
from a previous model of the lumbar spine [70]. T12-L5 
vertebrae and S1 reproduce in a reliable way the anatomy 
of spine. 
 
 
 
Table 1 – BMD, apparent density and Young’s modulus for the data corresponding to the study of López et al. (2010)[64]. 
Zone 
 
Standard 
BMD 
(mg/cm2) 
Apparent 
volumetric 
density 
(gr/cm3) 
Young 
modulus 
(MPa) 
Vertebral 
wall 1159 1.494 9593 
Outer 
vertebral 
endplates 
1159 1.494 9593 
Intermediate 
vertebral 
endplates 
610 1.186 4797 
Centre of 
vertebral 
endplates 
221 0.822 1599 
Apophyses 321 0.941 2398 
 
 
 
 
Figure 2 – Evolutionary algorithm for the prediction of fracture probability 
 Figure 3 – Complete FE model including vertebrae, discs and ligaments: a) Frontal view; b) Lateral view; c) Dorsal view 
The vertebrae were meshed by means of tetrahedral 
elements with quadratic approximation in the I-DEAS® 
program[71] as described in [70]. The mesh of the discs is 
essential for the correct reproduction of the biomechanical 
behaviour of the lumbar spine; in order to do this, each 
disc is divided into nucleus pulposus and annulus fibrosus 
with commonly accepted dimensions [72]. Each part is 
meshed separately, the nucleus by means of tetrahedra 
and the annulus by means of hexahedra and prisms with 
quadratic approximation. Later, nine layers (outer and 
four double crossed) of concentric fibres are added to the 
annulus. These layers are modelled by means of tension-
only elements, included in the hexahedra matrix, with 
variable orientation from the most internal to the most 
external (Figure 4), ranging from 35º to 80º, respecting at 
most the anatomical disposition [73]. 
Finally, the ligaments are modelled by means of 
tetrahedra and prisms with quadratic approximation; in 
addition, membrane elements have been used for capsular 
ligaments.  The dimensions of those soft tissues 
correspond to average anatomical measurements [72, 73]. 
The number of finite elements for every part is shown in 
Table 2. The total number of elements of the final mesh, 
obtained after a sensitivity analysis, is 447462. To this 
respect a mesh refinement was performed in order to 
achieve a convergence towards a minimum of the 
potential energy, both for the whole model and for each of 
its components, with a tolerance of 1% between 
consecutive meshes. 
The bone and ligament properties were taken from the 
bibliography. Concerning the bone, in [69] it is 
demonstrated that the centre of the vertebrae is less rigid 
than in the exterior zone.  For this reason the vertebrae are 
divided into four areas with variable modulus of elasticity 
(Figure 5). In addition, the corresponding properties are 
used for the cancellous bone. Material properties are 
included in Table 2.  
The behaviour of the nucleus pulposus, like a non-
compressible fluid, was simulated by means of the 
hyperelastic Mooney-Rivlin model (incompressible) 
incorporated in the Abaqus® version 6.12 materials library 
[74]. The fibres of the annulus exhibit a non-linear only 
tension behaviour approximated using different linear 
models for each layer considering their respective range 
of deformation [69]. The materials of the matrix and 
cartilage of the apophyses were simulated as elastic 
materials. Finally, the different ligaments present non-
linear only tension behaviour, included as a bilinear 
model in the strain range (Table 2) as with most of the 
reported FEM studies [69, 70]. 
As boundary conditions displacements in the wings of 
sacrum have been prevented (Figure 6(a)). As load 
condition a moment of 15 mN was considered acting on 
the upper face of vertebra T12 (Figure 6(b)), 
corresponding to the load producing the movement of 
flexion [70]. 
 
Figure 4 – Model of the inter-vertebral disk and its layers of fibres: a) Mesh of nucleus pulposus and annulus fibrosus; b) 
Mesh of fiber layers 
 
Figure 5 – Zones of different elastic properties in the vertebral body 
 
Figure 6 – Boundary conditions: a) Restrained displacements; b) Loads on T12 
Table 2 – Statistics for the FE model and mechanical properties of materials, for healthy lumbar spine, according with 
[70][Ibarz et al. (2013)] 
 
Material 
Young 
modulus 
(MPa) 
Poisson 
coefficient  
Element type 
Number of 
elements 
Outer vertebral endplates 12000 0.3 Tetrahedron 3578 
Intermediate vertebral endplates 6000 0.3 Tetrahedron 2244 
Centre of the vertebral endplates 2000 0.3 Tetrahedron 831 
Walls of the vertebral body 12000 0.3 Tetrahedron 37205 
Cancellous bone (inside vertebrae) 100 0.2 Tetrahedron 44954 
Posterior vertebra 3000 0.3 Tetrahedron 47134 
Cartilage 50 0.4 Wedge 3086 
Annulus fibrosus 4.2 0.45 Hexahedron 8288 
Nucleus pulposus (*) Incompressible material Tetrahedron 14410 
Annulus fiber layers 1 360 0.3 Truss (**) 592 
Annulus fiber layers 2 408 0.3 Truss (**) 592 
Annulus fiber layers 3 455 0.3 Truss (**) 592 
Annulus fiber layers 4 503 0.3 Truss (**) 592 
Annulus fiber layers 5 550 0.3 Truss (**) 296 
Ligament 
Young 
modulus 
(MPa) 
Transition 
strain (%) Element type 
Number of 
elements 
Anterior longitudinal ligament 7.8 
20.0 
12.0 
 
Wedge (**) 9046 
Posterior longitudinal ligament 10.0 
50.0 
11.0 Wedge (**) 3844 
Ligamentum flavum 15.0 
19.0 
6.2 Tetrahedron (**) 3042 
Intertransverse ligament 10.0 
59.0 
18.0 Tetrahedron (**) 6678 
Capsular ligament 7.5 
33.0 
25.0 Membrane (**) 3220 
Interspinous ligament 8.0 
15.0 
20.0 Tetrahedron (**) 2856 
Supraspinous ligament 10.0 
12.0 
14.0 Tetrahedron (**) 2657 
Iliolumbar ligament 7.8 
20.0 
12.0 
 
Wedge (**) 816 
(*) C01=0.0343 MPa; C10=0.1369 MPa. An elastic analysis with Young modulus of 1.0 MPa and Poisson ratio of 
0.49 was carried out with similar results and a volume change less than 0.6%. 
(**) Only tension 
The model has been used in predicting the evolution of 
vertebral fracture probability, by comparing the natural 
history and the expected evolution under different 
therapies. The study has been performed for a 65 years 
old patient with actual BMD values of 718 mg/cm2 for 
L1, 803 mg/cm2 for L2, 834 mg/cm2 for L3 and 883 
mg/cm2 for L4, respectively.  The period of study was ten 
years (from 65 to 75 years old). 
 
3 Results 
Firstly, adjustment models were applied both to BMD 
physiological curve (weighted average from [50] and the 
curves of patients under seven different therapies: oral 
ibandronate (100 mg/month) [51], oral ibandronate (150 
mg/month) [51], intravenous ibandronate (2 mg 
bimonthly) [52], intravenous ibandronate (3 mg quarterly) 
[52], strontium ranelate (2 g/day) [53], zoledronic acid (5 
mg/year) [54] and Denosumab (60 mg every six months) 
[55]. Figure 7 shows the different evolutionary curves 
obtained in each case, together with the interpolated 
curves for L1 vertebra. Despite the irregularity of some 
cases, the correlation coefficients have been 0.994 for 
natural BMD evolution curve, and in the range 0.992-
0.999 for BMD evolution curves corresponding to the 
different treatments. Similar curves were obtained for L2, 
L3 and L4 vertebrae, respectively. 
As can be seen in the graphics, patient treated with oral 
ibandronate showed a significant initial increase in bone 
density, more pronounced for 150 mg/month dose, which 
remained stable and with increasing trend until the end of 
the study period. The same evolution happens in the case 
of intravenous ibandronate. Strontium ranelate also leads 
to a remarkable increase in BMD during the study period; 
however, a more continuous increasing is observed, with 
less initial increments but with higher final values of 
BMD. Similar trends are observed for zoledronic acid and 
Denosumab, with a more continuous increasing in the last 
case. In opposition, the physiological curve (natural 
evolution) was characterized by a substantial and 
progressive decline in BMD. For L2, L3 and L4 vertebrae 
the same tendencies are obtained, starting with the 
corresponding BMD values. 
Figures 8(a), 8(c), 8(e) and 8(g) illustrate the evolution of 
average mechanical damage under natural conditions and 
under the seven proposed therapies for L1, L2, L3 and L4 
vertebrae, respectively. In the case of therapies which 
preserve BMD, and therefore bone stiffness, the 
mechanical damage value diminishes for every treatment. 
For every vertebra, strontium ranelate exhibits the highest 
decrease, whereas minimum decrease is achieved with 
oral ibandronate (150 mg/month). All the treatments 
manifest similar trends for every vertebra. Conversely to 
previous trends, for the natural BMD evolution, as bone 
stiffness decreases, the mechanical damage shows a 
significant increase (as it occurs in the natural history of 
BMD). 
As a final result, the evolutionary curves of fracture 
probability were obtained from the evolution of 
mechanical damage (Fig. 8). As can be seen, the fracture 
probability shows a marked increase in the natural 
evolution curve, ranging from a maximum of 5.53% for 
L1 to a minimum of 2.06% for L4. On the other hand, the 
curves of the treated patient show lower degrees of risk, 
depending on the therapy type. Thus, for L1 strontium 
ranelate produces a maximum fracture probability 
reduction of 16.20%, while oral ibandronate (150 
mg/month) produces a minimum fracture probability 
reduction of 8.53%. Similarly, for L2 strontium ranelate 
produces a maximum fracture probability reduction of 
5.85%, while oral ibandronate (150 mg/month) produces a 
minimum fracture probability reduction of 4.00%. For L3 
strontium ranelate produces a maximum fracture 
probability reduction of 4.65%, while oral ibandronate 
(150 mg/month) produces a minimum fracture probability 
reduction of 3.22%. Finally, For L4 strontium ranelate 
produces a maximum fracture probability reduction of 
3.09%, while oral ibandronate (150 mg/month) produces a 
minimum fracture probability reduction of 2.23%. In the 
best case, an improvement (fracture probability reduction) 
of 21.73% between natural evolution and treatment is 
obtained for L1.  
In addition to previous results, programmed subroutines 
make it possible to obtain damage and fracture probability 
maps and to identify high-risk zones of the vertebral 
body. Vertebral walls and external areas of vertebral end 
plates are the zones at greatest risk, in coincidence with 
the typical locations of osteoporotic fractures, 
characterized by a vertebral crushing due to the collapse 
of vertebral walls. It must be pointed out that the fracture 
probability maps doesn´t represent actual fracture zones, 
but zones with poorer bone mechanical strength due to 
cumulative damage. The actual fracture zone would be 
determined according loading scenario (impact, accidental 
loads, etc.). 
 
 Figure 7 – Fitting of BMD evolutionary curves: a) Natural evolution (polynomial, R2=0.994); b) oral ibandronate (100 
mg/month) (exponential, R2=0.999); c) oral ibandronate (150 mg/month) (exponential, R2=0.999); d) intravenous 
ibandronate (2 mg bimonthly) (exponential, R2=0.999); e) intravenous ibandronate (3 mg quarterly) (exponential, 
R2=0.998); f) strontium ranelate (2 g/day) (exponential, R2=0.999); g) zoledronic acid (5 mg/year) (exponential, R2=0.992); 
h) Denosumab (60 mg/6 months) (exponential, R2=0.999) 
 Figure 8 – Evolution of mechanical damage and fracture probability increment for natural BMD evolution and for the 
different treatments: a) Mechanical damage (L1); b) Fracture probability increment (L1); c) Mechanical damage (L2); d) 
Fracture probability increment (L2); e) Mechanical damage (L3); f) Fracture probability increment (L3); g) Mechanical 
damage (L4); h) Fracture probability increment (L4) 
4 Discussion 
The spinal localization of osteoporotic fractures are very 
common [75] and unfortunately many of these fractures 
are usually not diagnosed [12, 13]. It is essential to 
prevent the first vertebral fracture and therefore determine 
the risk of fracture is an important aid to the medical 
doctors for taking decision to prescribe treatment; so the 
availability of a tool to inform about of individualized 
fracture risk is very important. 
In this work, clinical data (BMD measures) and 
mechanical magnitudes related to bone strength have been 
combined in this tool for estimating the risk in 
osteoporotic patients. The mechanical properties of bone 
are updated from BMD values obtained from clinical data 
of untreated patients and in those under different 
treatments.  The model uses Damage and Fracture 
Mechanics concepts to evaluate the fracture probability in 
an evolutionary algorithm and can be used in a 
personalized way from BMD measurements in each case. 
Many studies have been carried out, both in the clinical 
[14-18, 20, 21, 23, 76] and the simulation fields [19, 28-
30, 32, 34, 39, 40, 77]. But a simple and reliable model, 
useful as a tool for diagnosis and prevention in our daily 
practice, has not yet been achieved. The proposed model 
can contribute to the development of diagnostic tools for 
detection of early stages of osteoporosis. It may also be 
helpful for treatment decisions in selected patients. 
There are few studies, besides the tool FRAX®, to 
determine the risk of vertebral fracture. Some studies 
assess the risk of new fracture after the diagnosis of first 
vertebral fracture by using clinical data [15]. Other 
studied employed logistic regression models based in 
clinical data and BMD to determine the vertebral fracture 
risk [78]. Statistical models are currently the most reliable 
in the literature [13, 14, 18, 76], regardless of mechanical 
issues involving bone strength estimated for different 
conditions and ages. The development of new techniques 
for measuring BMD has focused much of the recent 
research in the clinical setting, but the mechanical aspects 
have not been adequately studied [16, 17, 20, 21]. Only in 
Kanis et al. [79] a new method derived from DXA 
measures was developed for bone strength assessment. 
Concerning FE simulation, the incorporation of the latest 
imaging techniques (QCT) and BMD measurement 
(DXA) [19, 29, 39, 77] has allowed the improvement of 
these models. However, most of models don’t consider 
essential aspects in fracture analysis. Nonetheless, all 
models assume that bone mineral density is the basic 
measurement, and it should therefore be used as a 
benchmark in predicting fracture risk.  
From a mechanical point of view, the exposition of the 
bone to cyclic loads of high value in a damaged bone, 
once the degenerative process is started, decreases its 
strength over the time and produces a cumulative damage 
which can lead to a final fracture. It seems apparent that 
Damage Mechanics and Fracture Mechanics criteria 
should be incorporated in any model intending to obtain 
reliable results. In this regard, the model combines all 
these requirements. The developed model takes into 
account the above criteria and combines information of 
clinical and mechanical magnitudes, providing more 
complete information about the risk of fracture in the mid 
and long term, according to the different medical 
treatments. 
Any case, the predictions of the proposed method, based 
on BMD measurements and mechanical magnitudes are 
consistent with the clinical models for predicting 
osteoporotic fractures. In a previous work published by 
the authors [80], the good correlation between predictions 
of the proposed method and the FRAX was demonstrated 
in application to the femur, for a sample size of 220 
patients of both sexes aged between 60 and 89 years. 
The model presents some limitations, first, as it is well 
know that life style and changes in habits can affect 
BMD, so the supposition of crack growth under 
monotonic loading adopted in the model may be a suitable 
approximation to predict evolution in older people with 
osteoporosis, but not in people with variation in their life 
habits where range and type of load cycles change 
continuously. In the second term, a more accurate bone 
density distribution by individual elements in the mesh 
could be used, planning a complete collection of BMD 
data, by means of DXA or CT scan images. More 
complex mechanical damage models could be 
incorporated taken as basis the model shown, including 
mechanical behaviour of anisotropic or mixed models. It 
could also be possible to include crack growth models 
fitting to the results from in vitro bone fracture. Despite 
DXA measurements just quantify bone mass and not bone 
quality, it is widely accepted as a macroscopic indicator 
of bone strength and stiffness and also that micro-
fractures exert an important influence on the mechanical 
strength of the bone. In this respect, the influence of 
trabecular architecture (bone quality) should be 
considered in the model. On the other hand, patient-
specific models are needed [81], and the effects of 
intervertebral discs should be considered [82], due to the 
influence of the vertebral geometry and  the mechanical 
properties of discs in the biomechanical behaviour of the 
whole lumbar spine. These topics should be addressed in 
future studies. Finally, clinical trials are needed to 
validate the proposed model in order to apply it to the 
clinical practice helping for treatment decisions. 
Since this is a first application to the complete lumbar 
spine, we used for simplicity a single model. However, 
the methodology for the adjustment of the model to 
specific patients has been developed and it has been 
successfully tested in previous studies [80]. 
The use of BMD measurements from DXA as input data 
in the model is due to it is the most commonly available 
clinical technique. Obviously, more complete data 
obtained through more powerful techniques (3D scanner, 
for example), would improve the reliability of the method. 
 
4 Conclusions 
A mechanical model based on Damage and Fracture 
Mechanics and DXA measurements, for predicting the 
probability of fracture in osteoporotic patients has been 
applied to seven different treatments, identifying the 
reduction achieved for the fracture probability in every 
case. The model represents a first step towards the 
development of new tools for prediction of fracture risk. 
The incorporation of clinical measurements and 
simulation results will be useful for an individualized 
monitoring and treatment in specific patients. 
The developed model is not intended to replace the 
models based solely on BMD, but to complement it 
including mechanical magnitudes involved in the 
fracturing process, providing more information on the 
mechanical state of the bone in every analyzed age. 
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